Under one in 10 people eligible to benefit from obesity jabs including Wegovy have access to them, states the WHO as it releases its inaugural advice on the medications.
Given over a billion individuals worldwide now living with obesity, it is advocating for more widespread and fairer access to this class of drugs.
According to forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken.
"The new guidance acknowledges that obesity is a lifelong illness that can be treated with comprehensive and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are significant obstacles to broad access to the injections that can aid individuals in losing significant body mass, notes the organization.
Weight-Loss Drug Supply Crisis
Even in the present best projected outlook, the manufacturing of such drugs might only reach approximately 100 million people – less than 10% of eligible patients, per the WHO.
The guideline calls on nations and manufacturers to widen access, via measures such as voluntary licensing.
The intellectual property rights on a key compound – the primary component of the drug Wegovy – is scheduled to end in multiple nations in 2026.
The Way Obesity Jabs Operate
GLP-1 drugs imitate a natural hormone to reduce digestion speed, reduce hunger and increase feelings of fullness so individuals eat less.
Patients typically see weight reduction in the initial weeks of beginning the regular doses.
Research indicates users may see weight return a year later of discontinuing the treatment, when their normal appetite come back.
To be above a healthy weight elevates your risk for developing medical conditions, including diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight impacts individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the WHO.
